schliessen

Filtern

 

Bibliotheken

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia

The effects on sleep of lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor administered as a lipophilic lactone prodrug, and pravastatin, an inhibitor administered in its active, hydrophilic, open-acid form, were compared by polysomnographic sleep monitoring. Twenty-four men wit... Full description

Journal Title: The American journal of cardiology 1994, Vol.73 (12), p.876-880
Main Author: Partinen, Markku
Other Authors: Pihl, Susan , Strandberg, Timmo , Vanhanen, Hannu , Murtomäki, Elina , Block, Gilbert , Neafus, Richard , Haigh, Jeremy , Miettinen, Tatu , Reines, Scott
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Elsevier Inc
ID: ISSN: 0002-9149
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_journals_230345414
title: Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia
format: Article
creator:
  • Partinen, Markku
  • Pihl, Susan
  • Strandberg, Timmo
  • Vanhanen, Hannu
  • Murtomäki, Elina
  • Block, Gilbert
  • Neafus, Richard
  • Haigh, Jeremy
  • Miettinen, Tatu
  • Reines, Scott
subjects:
  • Adult
  • Aged
  • Biological and medical sciences
  • Cardiovascular disease
  • Double-Blind Method
  • Drug therapy
  • General and cellular metabolism. Vitamins
  • Humans
  • Hypercholesterolemia
  • Hypercholesterolemia - drug therapy
  • Hypercholesterolemia - physiopathology
  • Lipoproteins - blood
  • Lovastatin
  • Lovastatin - adverse effects
  • Lovastatin - therapeutic use
  • Male
  • Medical research
  • Medical sciences
  • Middle Aged
  • Pharmacology. Drug treatments
  • Physiological aspects
  • Polysomnography
  • Pravastatin
  • Pravastatin - adverse effects
  • Pravastatin - therapeutic use
  • Sleep
  • Sleep - drug effects
ispartof: The American journal of cardiology, 1994, Vol.73 (12), p.876-880
description: The effects on sleep of lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor administered as a lipophilic lactone prodrug, and pravastatin, an inhibitor administered in its active, hydrophilic, open-acid form, were compared by polysomnographic sleep monitoring. Twenty-four men with primary hypercholesterolemia (low-density lipoprotein 4 to 7 mmol/liter) each received 2 of the following 3 treatments in a randomized, incomplete block, crossover design study: lovastatin (40 mg/day), pravastatin (40 mg/day), and placebo. Test drug was administered once daily for 4 weeks during each half of the crossover study. Subjective sleep assessments were obtained throughout each treatment period, and polysomnographic recordings were obtained at the end of the 4-week treatment periods. Treatment periods were separated by a 1-week washout. Lovastatin did not differ from placebo regarding any polysomnographic parameter except “number of entries to wake,” for which it produced fewer entries (i.e., change was in the direction of improvement). Pravastatin did not differ from placebo regarding any polysomnographic measures, but was associated with worsening in relation to lovastatin in the following parameters: sleep efficiency, entries to wake, percent rapid eye movement sleep, wake time during sleep, and total wake time. For each of these 4 parameters, although neither drug showed marked differences from placebo, the mean change in the lovastatin group was in the direction of improved sleep, whereas the change in the pravastatin group was in the direction of disturbed sleep. Neither lovastatin nor pravastatin had any effect on subjective, qualitative sleep ratings. Treatment with lovastatin produced no deleterious effects on sleep after 4 weeks of treatment in men with primary hyper-cholesterolemia; pravastatin was similarly without effect. Thus, the inherent lipophilicity of the closed lactone 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor lovastatin did not produce any detectable changes in sleep in this patient cohort.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-9149
fulltext: fulltext
issn:
  • 0002-9149
  • 1879-1913
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.7382128
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_journals_230345414
sourceformatXML
sourcesystemPC
galeidA15457970
sourcerecordidA15457970
originalsourceidFETCH-LOGICAL-c493t-7c9293609a45064e367f246e4ed7d85ee7449e21248ad08363ac651b0f8e7edd3
addsrcrecordideNqFkV1rFTEQhoMo9bT6DxQW8UIvVjOb2c3GC6Ec6gcUvKnXIU0mNmV3syZ7Cv33Zj2Ho4goCYSZeeYj8zL2DPgb4NC95Zw3tQJUrxS-VrwHrOEB20AvVQ0KxEO2OSKP2WnOt8UEaLsTdtJDjz00G3a1jeNsUshxqqKvyHuyS66KlQeiefUN8c7kxSxhqszkqjmZo13uzf1Myd7EgfJCqTxjME_YI2-GTE8P7xn7-uHiavupvvzy8fP2_LK2qMRSS6saJTquDLa8QxKd9A12hOSk61siiaiogQZ743gvOmFs18I19z1Jck6csRf7unOK33dlAH0bd2kqLXUjuMAWAX9B38xAOkw-LsnYMWSrz6HFVirJC1T_BSrHlf_YOJEPxf87j3vepphzIq_nFEaT7jVwvaqj19XrdfVaof6pjoaS9vww8O56JHdMOshR4i8PcZOtGXwykw35iCFXslAFe_dHdxtWQeJUpg7D_2Z4v0-mosxdoKSzDTRZciEV7bWL4d8FfgCqLruX
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid230345414
display
typearticle
titleComparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia
sourceAlma/SFX Local Collection
creatorPartinen, Markku ; Pihl, Susan ; Strandberg, Timmo ; Vanhanen, Hannu ; Murtomäki, Elina ; Block, Gilbert ; Neafus, Richard ; Haigh, Jeremy ; Miettinen, Tatu ; Reines, Scott
creatorcontribPartinen, Markku ; Pihl, Susan ; Strandberg, Timmo ; Vanhanen, Hannu ; Murtomäki, Elina ; Block, Gilbert ; Neafus, Richard ; Haigh, Jeremy ; Miettinen, Tatu ; Reines, Scott
descriptionThe effects on sleep of lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor administered as a lipophilic lactone prodrug, and pravastatin, an inhibitor administered in its active, hydrophilic, open-acid form, were compared by polysomnographic sleep monitoring. Twenty-four men with primary hypercholesterolemia (low-density lipoprotein 4 to 7 mmol/liter) each received 2 of the following 3 treatments in a randomized, incomplete block, crossover design study: lovastatin (40 mg/day), pravastatin (40 mg/day), and placebo. Test drug was administered once daily for 4 weeks during each half of the crossover study. Subjective sleep assessments were obtained throughout each treatment period, and polysomnographic recordings were obtained at the end of the 4-week treatment periods. Treatment periods were separated by a 1-week washout. Lovastatin did not differ from placebo regarding any polysomnographic parameter except “number of entries to wake,” for which it produced fewer entries (i.e., change was in the direction of improvement). Pravastatin did not differ from placebo regarding any polysomnographic measures, but was associated with worsening in relation to lovastatin in the following parameters: sleep efficiency, entries to wake, percent rapid eye movement sleep, wake time during sleep, and total wake time. For each of these 4 parameters, although neither drug showed marked differences from placebo, the mean change in the lovastatin group was in the direction of improved sleep, whereas the change in the pravastatin group was in the direction of disturbed sleep. Neither lovastatin nor pravastatin had any effect on subjective, qualitative sleep ratings. Treatment with lovastatin produced no deleterious effects on sleep after 4 weeks of treatment in men with primary hyper-cholesterolemia; pravastatin was similarly without effect. Thus, the inherent lipophilicity of the closed lactone 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor lovastatin did not produce any detectable changes in sleep in this patient cohort.
identifier
0ISSN: 0002-9149
1EISSN: 1879-1913
2DOI: 10.1016/0002-9149(94)90814-1
3PMID: 8184812
4CODEN: AJCDAG
languageeng
publisherNew York, NY: Elsevier Inc
subjectAdult ; Aged ; Biological and medical sciences ; Cardiovascular disease ; Double-Blind Method ; Drug therapy ; General and cellular metabolism. Vitamins ; Humans ; Hypercholesterolemia ; Hypercholesterolemia - drug therapy ; Hypercholesterolemia - physiopathology ; Lipoproteins - blood ; Lovastatin ; Lovastatin - adverse effects ; Lovastatin - therapeutic use ; Male ; Medical research ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Physiological aspects ; Polysomnography ; Pravastatin ; Pravastatin - adverse effects ; Pravastatin - therapeutic use ; Sleep ; Sleep - drug effects
ispartofThe American journal of cardiology, 1994, Vol.73 (12), p.876-880
rights
01994
11994 INIST-CNRS
2COPYRIGHT 1994 Elsevier B.V.
3Copyright Elsevier Sequoia S.A. May 1, 1994
lds50peer_reviewed
citedbyFETCH-LOGICAL-c493t-7c9293609a45064e367f246e4ed7d85ee7449e21248ad08363ac651b0f8e7edd3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4097123$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8184812$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Partinen, Markku
1Pihl, Susan
2Strandberg, Timmo
3Vanhanen, Hannu
4Murtomäki, Elina
5Block, Gilbert
6Neafus, Richard
7Haigh, Jeremy
8Miettinen, Tatu
9Reines, Scott
title
0Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia
1The American journal of cardiology
addtitleAm J Cardiol
descriptionThe effects on sleep of lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor administered as a lipophilic lactone prodrug, and pravastatin, an inhibitor administered in its active, hydrophilic, open-acid form, were compared by polysomnographic sleep monitoring. Twenty-four men with primary hypercholesterolemia (low-density lipoprotein 4 to 7 mmol/liter) each received 2 of the following 3 treatments in a randomized, incomplete block, crossover design study: lovastatin (40 mg/day), pravastatin (40 mg/day), and placebo. Test drug was administered once daily for 4 weeks during each half of the crossover study. Subjective sleep assessments were obtained throughout each treatment period, and polysomnographic recordings were obtained at the end of the 4-week treatment periods. Treatment periods were separated by a 1-week washout. Lovastatin did not differ from placebo regarding any polysomnographic parameter except “number of entries to wake,” for which it produced fewer entries (i.e., change was in the direction of improvement). Pravastatin did not differ from placebo regarding any polysomnographic measures, but was associated with worsening in relation to lovastatin in the following parameters: sleep efficiency, entries to wake, percent rapid eye movement sleep, wake time during sleep, and total wake time. For each of these 4 parameters, although neither drug showed marked differences from placebo, the mean change in the lovastatin group was in the direction of improved sleep, whereas the change in the pravastatin group was in the direction of disturbed sleep. Neither lovastatin nor pravastatin had any effect on subjective, qualitative sleep ratings. Treatment with lovastatin produced no deleterious effects on sleep after 4 weeks of treatment in men with primary hyper-cholesterolemia; pravastatin was similarly without effect. Thus, the inherent lipophilicity of the closed lactone 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor lovastatin did not produce any detectable changes in sleep in this patient cohort.
subject
0Adult
1Aged
2Biological and medical sciences
3Cardiovascular disease
4Double-Blind Method
5Drug therapy
6General and cellular metabolism. Vitamins
7Humans
8Hypercholesterolemia
9Hypercholesterolemia - drug therapy
10Hypercholesterolemia - physiopathology
11Lipoproteins - blood
12Lovastatin
13Lovastatin - adverse effects
14Lovastatin - therapeutic use
15Male
16Medical research
17Medical sciences
18Middle Aged
19Pharmacology. Drug treatments
20Physiological aspects
21Polysomnography
22Pravastatin
23Pravastatin - adverse effects
24Pravastatin - therapeutic use
25Sleep
26Sleep - drug effects
issn
00002-9149
11879-1913
fulltexttrue
rsrctypearticle
creationdate1994
recordtypearticle
recordideNqFkV1rFTEQhoMo9bT6DxQW8UIvVjOb2c3GC6Ec6gcUvKnXIU0mNmV3syZ7Cv33Zj2Ho4goCYSZeeYj8zL2DPgb4NC95Zw3tQJUrxS-VrwHrOEB20AvVQ0KxEO2OSKP2WnOt8UEaLsTdtJDjz00G3a1jeNsUshxqqKvyHuyS66KlQeiefUN8c7kxSxhqszkqjmZo13uzf1Myd7EgfJCqTxjME_YI2-GTE8P7xn7-uHiavupvvzy8fP2_LK2qMRSS6saJTquDLa8QxKd9A12hOSk61siiaiogQZ743gvOmFs18I19z1Jck6csRf7unOK33dlAH0bd2kqLXUjuMAWAX9B38xAOkw-LsnYMWSrz6HFVirJC1T_BSrHlf_YOJEPxf87j3vepphzIq_nFEaT7jVwvaqj19XrdfVaof6pjoaS9vww8O56JHdMOshR4i8PcZOtGXwykw35iCFXslAFe_dHdxtWQeJUpg7D_2Z4v0-mosxdoKSzDTRZciEV7bWL4d8FfgCqLruX
startdate1994
enddate1994
creator
0Partinen, Markku
1Pihl, Susan
2Strandberg, Timmo
3Vanhanen, Hannu
4Murtomäki, Elina
5Block, Gilbert
6Neafus, Richard
7Haigh, Jeremy
8Miettinen, Tatu
9Reines, Scott
general
0Elsevier Inc
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
107QO
117TS
128FD
13FR3
14K9.
15P64
sort
creationdate1994
titleComparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia
authorPartinen, Markku ; Pihl, Susan ; Strandberg, Timmo ; Vanhanen, Hannu ; Murtomäki, Elina ; Block, Gilbert ; Neafus, Richard ; Haigh, Jeremy ; Miettinen, Tatu ; Reines, Scott
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c493t-7c9293609a45064e367f246e4ed7d85ee7449e21248ad08363ac651b0f8e7edd3
rsrctypearticles
prefilterarticles
languageeng
creationdate1994
topic
0Adult
1Aged
2Biological and medical sciences
3Cardiovascular disease
4Double-Blind Method
5Drug therapy
6General and cellular metabolism. Vitamins
7Humans
8Hypercholesterolemia
9Hypercholesterolemia - drug therapy
10Hypercholesterolemia - physiopathology
11Lipoproteins - blood
12Lovastatin
13Lovastatin - adverse effects
14Lovastatin - therapeutic use
15Male
16Medical research
17Medical sciences
18Middle Aged
19Pharmacology. Drug treatments
20Physiological aspects
21Polysomnography
22Pravastatin
23Pravastatin - adverse effects
24Pravastatin - therapeutic use
25Sleep
26Sleep - drug effects
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Partinen, Markku
1Pihl, Susan
2Strandberg, Timmo
3Vanhanen, Hannu
4Murtomäki, Elina
5Block, Gilbert
6Neafus, Richard
7Haigh, Jeremy
8Miettinen, Tatu
9Reines, Scott
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9Biotechnology Research Abstracts
10Physical Education Index
11Technology Research Database
12Engineering Research Database
13ProQuest Health & Medical Complete (Alumni)
14Biotechnology and BioEngineering Abstracts
jtitleThe American journal of cardiology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Partinen, Markku
1Pihl, Susan
2Strandberg, Timmo
3Vanhanen, Hannu
4Murtomäki, Elina
5Block, Gilbert
6Neafus, Richard
7Haigh, Jeremy
8Miettinen, Tatu
9Reines, Scott
formatjournal
genrearticle
ristypeJOUR
atitleComparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia
jtitleThe American journal of cardiology
addtitleAm J Cardiol
date1994
risdate1994
volume73
issue12
spage876
epage880
pages876-880
issn0002-9149
eissn1879-1913
codenAJCDAG
abstractThe effects on sleep of lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor administered as a lipophilic lactone prodrug, and pravastatin, an inhibitor administered in its active, hydrophilic, open-acid form, were compared by polysomnographic sleep monitoring. Twenty-four men with primary hypercholesterolemia (low-density lipoprotein 4 to 7 mmol/liter) each received 2 of the following 3 treatments in a randomized, incomplete block, crossover design study: lovastatin (40 mg/day), pravastatin (40 mg/day), and placebo. Test drug was administered once daily for 4 weeks during each half of the crossover study. Subjective sleep assessments were obtained throughout each treatment period, and polysomnographic recordings were obtained at the end of the 4-week treatment periods. Treatment periods were separated by a 1-week washout. Lovastatin did not differ from placebo regarding any polysomnographic parameter except “number of entries to wake,” for which it produced fewer entries (i.e., change was in the direction of improvement). Pravastatin did not differ from placebo regarding any polysomnographic measures, but was associated with worsening in relation to lovastatin in the following parameters: sleep efficiency, entries to wake, percent rapid eye movement sleep, wake time during sleep, and total wake time. For each of these 4 parameters, although neither drug showed marked differences from placebo, the mean change in the lovastatin group was in the direction of improved sleep, whereas the change in the pravastatin group was in the direction of disturbed sleep. Neither lovastatin nor pravastatin had any effect on subjective, qualitative sleep ratings. Treatment with lovastatin produced no deleterious effects on sleep after 4 weeks of treatment in men with primary hyper-cholesterolemia; pravastatin was similarly without effect. Thus, the inherent lipophilicity of the closed lactone 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor lovastatin did not produce any detectable changes in sleep in this patient cohort.
copNew York, NY
pubElsevier Inc
pmid8184812
doi10.1016/0002-9149(94)90814-1